144 related articles for article (PubMed ID: 20413726)
1. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.
Gnoth MJ; Buetehorn U; Muenster U; Schwarz T; Sandmann S
J Pharmacol Exp Ther; 2011 Jul; 338(1):372-80. PubMed ID: 21515813
[TBL] [Abstract][Full Text] [Related]
3. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
[TBL] [Abstract][Full Text] [Related]
4. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Ohashi R; Kamikozawa Y; Sugiura M; Fukuda H; Yabuuchi H; Tamai I
Drug Metab Dispos; 2006 May; 34(5):793-9. PubMed ID: 16455807
[TBL] [Abstract][Full Text] [Related]
5. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
[TBL] [Abstract][Full Text] [Related]
6. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
8. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
10. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
12. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
13. Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
Bonhomme-Faivre L; Benyamina A; Reynaud M; Farinotti R; Abbara C
Addict Biol; 2008 Sep; 13(3-4):295-300. PubMed ID: 18331373
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
15. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier.
Murata M; Tamai I; Kato H; Nagata O; Tsuji A
J Pharmacol Exp Ther; 1999 Jul; 290(1):51-7. PubMed ID: 10381759
[TBL] [Abstract][Full Text] [Related]
16. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
Agarwal S; Sane R; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
[TBL] [Abstract][Full Text] [Related]
17. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
Schinkel AH; Wagenaar E; van Deemter L; Mol CA; Borst P
J Clin Invest; 1995 Oct; 96(4):1698-705. PubMed ID: 7560060
[TBL] [Abstract][Full Text] [Related]
18. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.
Ohe T; Sato M; Tanaka S; Fujino N; Hata M; Shibata Y; Kanatani A; Fukami T; Yamazaki M; Chiba M; Ishii Y
Drug Metab Dispos; 2003 Oct; 31(10):1251-4. PubMed ID: 12975334
[TBL] [Abstract][Full Text] [Related]
19. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier.
Milane A; Fernandez C; Vautier S; Bensimon G; Meininger V; Farinotti R
J Neurochem; 2007 Oct; 103(1):164-73. PubMed ID: 17635670
[TBL] [Abstract][Full Text] [Related]
20. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
